The latest experimental GLP-1 from Eli Lilly isn’t just a diabetes drug — it also facilitates weight loss. Known as “triple-G,” injectable retatrutide levies a triple whammy on the GLP-1, GIP and ...

The award-winning growth firm marks its anniversary by leading Indie Week’s inaugural pitch competition spotlighting innovation in independent music. As it celebrates five years of scaling high-growth ...

Eli Lilly’s ‘triple G’ agonist, retatrutide, has secured another late-stage win in obesity, though analysts question whether the drug will outcompete the company’s market-leading medication, ...

Eli Lilly's triple-G agonist candidate, retatrutide, led to significant reductions in both blood sugar levels and body weight in its first phase 3 diabetes trial, suggesting a potentially ...

Eli Lilly's triple G agonist retatrutide has achieved impressive weight loss in patients with type 2 diabetes and obesity, boosting its credentials as the next big thing in cardiometabolic diseases.

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...